| __timestamp | Eli Lilly and Company | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 26684000 |
| Thursday, January 1, 2015 | 6533000000 | 29829000 |
| Friday, January 1, 2016 | 6452000000 | 39578000 |
| Sunday, January 1, 2017 | 6588100000 | 43277000 |
| Monday, January 1, 2018 | 5975100000 | 48645000 |
| Tuesday, January 1, 2019 | 6213800000 | 52934000 |
| Wednesday, January 1, 2020 | 6121200000 | 61349000 |
| Friday, January 1, 2021 | 6431600000 | 127125000 |
| Saturday, January 1, 2022 | 6440400000 | 136106000 |
| Sunday, January 1, 2023 | 6941200000 | 133175999 |
| Monday, January 1, 2024 | 8593800000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Eli Lilly and Company, a stalwart in the industry, and HUTCHMED (China) Limited, a rising star, offer a fascinating study in contrasts. Over the past decade, Eli Lilly's SG&A expenses have hovered around $6.4 billion annually, showing a steady increase of about 5% from 2014 to 2023. In contrast, HUTCHMED's expenses, though significantly lower, have surged by nearly 400% in the same period, reflecting its aggressive expansion strategy. While Eli Lilly's expenses are substantial, they represent a smaller percentage of its overall revenue, indicating efficient cost management. HUTCHMED, however, is investing heavily in growth, which could pay off in the long run. This comparison highlights the different strategies companies employ to balance cost management with growth ambitions.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Bristol-Myers Squibb Company
Eli Lilly and Company or Sanofi: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Eli Lilly and Company and Corcept Therapeutics Incorporated
Eli Lilly and Company and Novavax, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and HUTCHMED (China) Limited
Comparing SG&A Expenses: argenx SE vs HUTCHMED (China) Limited Trends and Insights
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs HUTCHMED (China) Limited
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited
Selling, General, and Administrative Costs: ADMA Biologics, Inc. vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.
HUTCHMED (China) Limited and MannKind Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing HUTCHMED (China) Limited and MiMedx Group, Inc.